Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Mol Cancer Res. 2017 Feb 14;15(6):765–775. doi: 10.1158/1541-7786.MCR-16-0183

Figure 1. Breast cancer and hTERT-HME1 cell lines treated with PI3K inhibitors.

Figure 1

A, levels of pAktS473, pAktT308 and total Akt following a 1 hour treatment with either DMSO or 1μM inhibitor (pan PI3Ki: GDC-0941, PI3K-αi: BYL719, PI3K-βi: AZD6482). B–D, kill curves generated from resazurin proliferation assays with GDC-0941 (B), BYL719 (C) and AZD6482 (D).